Join
Live feed
·
PRReleasevia Quantisnow
enGene Therapeutics Inc. logo

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

ByQuantisnow·Wall Street's wire, on your screen.
ENGN· enGene Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENGN (enGene Therapeutics Inc.) and more on Quantisnow.